Can Autoimmune Antibodies Explain Blood Clots in COVID-19?
The NIH-supported study, Prothrombotic Autoantibodies in Serum from Patients Hospitalized with COVID-19, is featured in the NIH Director's Blog. Read more.
New Cause of COVID-19 Blood Clots Identified
Yu (Ray) Zuo, MD; Yogen Kanthi, MD; and Jason Knight, MD, PhD find that a significant percentage of patients hospitalized with COVID were positive for autoantibodies that create blood clots. Read more.
Taubman Institute Supports First U-M Based COVID Study
Drs. Jason Knight, Yogen Kanthi, and Ray Zuo launch a clinical trial of a drug they believe may address the deadly blood clots that form in some patients with COVID-19. Read more.
UROP Blue Ribbon Awardee in the Knight Lab
Undergraduate Research Opportunity Program (UROP) student, Diane Chiang, was honored with the Blue Ribbon Award, given to students for having an exemplary capstone research poster and presentation. Read more.
Neutrophil Extracellular Traps (NETs) May Augur Severe COVID-19
Dr. Ray Zuo, Dr. Yogen Kanthi, and Dr. Jason Knight’s research that looked at the relationship between NETs and severe cases of COVID-19 is highlighted in The Scientist. Read more.
‘Spider-Man’ Immune Response May Promote Severe COVID-19
Clinical trials have begun to test drugs that counter toxic molecular webs linked to lung distress. Read more.
Higher Levels of NETs in Blood Associated with More Severe COVID-19
Ray Zuo, MD; Yogen Kanthi, MD; and Jason Knight, MD, PhD find a connection between destructive white blood cells and a more severe disease course in patients with COVID-19. Read more.
U-M Research Lab Opens to Explore New Treatment Targets for Patients with COVID-19
Yogendra Kanthi, MD and Jason Knight, MD, PhD were selected as recipients of the Frankel Cardiovascular Center “COVID-19: CV Impact Research Ignitor Grant”. Read more.
Rheumatology Research Foundation Investigator Award
Dr. Ray Zuo receives the Investigator Award, which is given to junior investigators in the period between completing post-doctoral fellowship training while being competitive for more significant funding and establishing themselves as independent investigators. Read more.
Rheumatology Research Foundation Edmund L. Dubois, MD Memorial Lectureship
Dr. Jason Knight is selected for the Edmund L. Dubois, MD Memorial Lectureship, which is given annually to an outstanding investigator in the area of lupus research. Read more.
Division of Rheumatology Spotlight - Dr. Ray Zuo
Ray Zuo, MD joined Michigan Medicine on November 1, 2019 as a Clinical Assistant Professor in the Division of Rheumatology. Dr. Zuo's focus is on Antiphospholipid Syndrome (APS) and is working on the APS Program with Dr. Jason Knight. Read more.
Lupus Research Alliance Target Identification in Lupus Grants Awarded
Jason Knight, MD, PhD is awarded a Lupus Research Alliance grant to study whether a stress-sensing protein spurs neutrophils to release NETs in patients with lupus. Read more.
Marvin and Betty Danto Research Professorship of Connective Tissue Research
Jason Knight, MD, PhD is named Marvin and Betty Danto Research Professor of Connective Tissue Research.
Q&A with New Research Fellow, Dr. Hui Shi
Hui Shi, MD, PhD is a new research fellow and the latest addition to Dr. Jason Knight’s lab. Prior to coming to Ann Arbor, Dr. Shi worked as a rheumatologist at Shanghai Ruijin Hospital, a well-known hospital in China. Read more.
Impeding White Blood Cells in Antiphospholipid Syndrome Reduced Blood Clots
A new study examined APS at the cellular level and found that two drugs reduced development of blood clots in mice affected with the condition. Read more.
Division of Rheumatology Spotlight - Dr. Jason Knight
Jason S. Knight, MD, PhD earned both his MD and PhD degrees from the University of Michigan, and completed the majority of his PhD thesis while at the University of Pennsylvania. Read more.
Lupus Research Alliance Announces Nine Promising Novel Research Grant Awards
Dr. Jason Knight receives grant to determine whether neutrophil elastase is a good target for the development of a new type of treatment for people with lupus. Read more.